Datamonitor Healthcare interviewed two experts on schizophrenia based in the UK and US to gauge their views on currently available treatment options, pipeline drugs, and challenges with clinical trial design. The specific drugs discussed include Rexulti [4578/LUN], ALKS 3831 [AKLS], MIN-101 [NERV}, Nuplazid [ACAD], Latuda [4506], Xeplion [JNJ], Trevicta [JNJ], Abilify Maintena [4578], Aristada [ALKS], and Fanapt [VNDA]. The two interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first and second interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.